CN104730242A - Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof - Google Patents
Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof Download PDFInfo
- Publication number
- CN104730242A CN104730242A CN201510085335.2A CN201510085335A CN104730242A CN 104730242 A CN104730242 A CN 104730242A CN 201510085335 A CN201510085335 A CN 201510085335A CN 104730242 A CN104730242 A CN 104730242A
- Authority
- CN
- China
- Prior art keywords
- histotomy
- transfection reagent
- reagent box
- arginase
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof. The kit comprises the following components: mixed primary antibody of Arginase-1 and Glypian-3, mixed second antibody of alkaline phosphatase conjugated goat anti-rabbit second antibody and horse radish peroxidase labeled goat anti -mouse second antibody, chromogenic reagent AP-Red and DAB (Diaminobenzidine), and TBS (Tris buffer saline) buffer solution. Two immunohistochemical labels provided by the invention are used for auxiliary diagnosis of benign or malignant hepatocellular tumor and differentiation degrees of tumor, the two labels are displayed through staining label by different detection systems and utilizing the differences of target cells stained by each label, information quantity and differential staining on the same radiograph are improved, readability and accuracy of radiograph reading are increased, so that the double-stained kit has important significance to identification of benign or malignant hepatocellular tumor and differentiation degrees of tumor.
Description
Technical field
The present invention relates to immunohistochemistry field, more particularly, relate to a kind of two transfection reagent box and application thereof of, malignant tumour auxiliary diagnosis good for liver cell and auxiliary antidiastole liver cell is good, the two dye detecting method of the immunohistochemistry of malignant tumour.
Background technology
Liver cancer is a kind of serious harm human life and healthy malignant tumour, and its morbidity rate is in China in ascendant trend year by year, and this sick Resection Rate is low, and 5 years survival rates are less than the 2nd of 5%, Xian Ju China cancer cause of the death.The pathogenic factor of primary carcinoma of liver and clinical manifestation are comparatively complicated, lack specificity, often occur DISTANT METASTASES IN when clinical definite, and then delay treatment, and survival rates is low.Therefore the prevention of primary carcinoma of liver, Treatment and diagnosis are still the key subjects of current medical domain research.Hepatocellular carcinoma (HCC) is modal Characters of Primary Malignant Tumors of Liver, accounts for the 70%-85% of liver cancer.Rely on morphology to differentiate that HCC and other hepatoncus have difficulties completely, be not easily distinguishable.IHC can play an important role in the good Malignant mass of auxiliary diagnosis liver, but conventional antibody CEA (polyclonal), CD10, AFP etc. lack specificity and susceptibility, little to the help of diagnosis.
Summary of the invention
The technical problem to be solved in the present invention is, for the above-mentioned defect of prior art, a kind of two transfection reagent boxes formed by two kinds of sensitivity and all good immunohistochemical markers thing of specificity are provided, this pair of transfection reagent box are used for that auxiliary antidiastole liver cell is good, the discriminating of malignant tumour and tumor differentiation degree.
The technical solution adopted for the present invention to solve the technical problems is: the two transfection reagent boxes providing a kind of, malignant tumour auxiliary diagnosis good for liver cell, comprise mixing primary antibodie, described mixing primary antibodie is the mixed antibody of Arginase-1 and Glypian-3.
Of the present invention pair of transfection reagent box, wherein, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 90-110 and 90-110.
Of the present invention pair of transfection reagent box, wherein, this pair of transfection reagent box also comprises mixing two and resists, and described mixing two resists for the anti-mixed antibody anti-with horseradish peroxidase-labeled sheep anti mouse two of alkali phosphatase enzyme mark goat-anti rabbit two.
Of the present invention pair of transfection reagent box, wherein, this pair of transfection reagent box also comprises chromogenic reagent AP-Red and DAB, and TBS damping fluid.
The present invention also provides that a kind of described above pair of transfection reagent box is good auxiliary antidiastole liver cell, application in malignant tumour.
The present invention also provides a kind of nondiagnostic to differentiate, and liver cell is good, the detection method of malignant tumour, and wherein, use two transfection reagent box described above, its detection method comprises the following steps:
(1) dewaxing and aquation: before dewaxing, histotomy is placed on roasting sheet machine and toasts, be then placed in dimethylbenzene, absolute ethyl alcohol, 95% ethanol and distilled water successively and soak;
(2) antigen retrieval: histotomy in step (1) is placed in EDTA antigen retrieval buffers and boils reparation, cooling, tap water, distilled water immersion;
(3) close: in step (2), drip 3% hydrogen peroxide, incubated at room in histotomy, with distilled water flushing, TBS buffer solution for cleaning is also soaked;
(4) two dye: histotomy drips mixing primary antibodie in step (3), after incubated at room, TBS buffer solution for cleaning, drip mixing two and resist, through incubated at room, TBS buffer solution for cleaning, adds developer DAB and AP-Red and develops the color;
(5) redye: histotomy in step (4) is put into haematoxylin solution and redyes, TBS damping fluid returns indigo plant;
(6) dewater: histotomy in step (5) is placed in 95% ethanol, absolute ethyl alcohol soaks successively;
(7) transparent: histotomy in step (6) to be placed in dimethylbenzene and to soak;
(8) mounting.
Detection method of the present invention, wherein, also comprise the pre-treatment step to histotomy in step (1), this histotomy 10% neutral formalin is fixed, and histotomy thickness is 2-5 μm.
Implement two transfection reagent box and the application thereof of a kind of, malignant tumour auxiliary diagnosis good for liver cell of the present invention, there is following beneficial effect:
Two kinds of Immunohistochemical Labelling things provided by the invention are used for that auxiliary antidiastole liver cell is good, the differentiation degree of malignant tumour and tumour, and to two kinds of different detection systems of label, utilize the target cell difference that each self-marker dyes, shown by dye marker, improve in the quantity of information of same slice, thin piece and differentiation dyeing, add readability and the degree of accuracy of diagosis, the discriminating for the differentiation degree of good, malignant hepatocytes tumour and tumour is significant.
Accompanying drawing explanation
Below in conjunction with drawings and Examples, the invention will be further described, in accompanying drawing:
Fig. 1 is the expression of Arginase-1 and Glypican-3 in liver tubercle hyperplastic tissue;
Fig. 2 is the expression of Arginase-1 and Glypican-3 in low differentiation liver cancer tissue;
Fig. 3 is the expression for Arginase-1 and Glypican-3 in differentiated liver cancer tissue.
Embodiment
Below, by reference to the accompanying drawings and embodiment, the present invention is described further:
The laboratory operating procedures that the present invention relates to is the step of this area routine, and material used is commercially available.
Arginase-1 (ARG1) is a kind of double-core manganese metalloproteinases, can catalysis arginine to the hydrolysis of ornithine and urea.Find in research process of the present invention: Arginase-1 is as the key enzyme of a urea cycle, expression in the liver cell of normal liver tissue has very high specificity, and bile duct epithelial cell, sinusoidal endothelial cell, Kupffer Cell and vascular endothelial cell are not all expressed.Express at the different hepatocellular carcinoma of differentiation that there were significant differences, at the expression rate of the hepatocellular carcinoma of high, middle differentiation up to more than 92%, and express hardly in low differentiated hepatocellular liver cancer.
Glypican-3 (glypican-3) is a kind of heparin sulfate glycoprotein and carcinomebryonic antigen, and the gene of this albumen of encoding is positioned at Xq26.Undue growth syndrome is relevant with the gene of this gene delection.Glypican-3 is expressed in Embryo liver, kidney, lung tissue and placenta tissue Trophocyte layer, and in neoplastic tissue, in liver cancer, yolk sac tumor, choriocarcinoma, melanoma, visible Glypican-3 expresses, and does not express in its hetero-organization.Find in research of the present invention to express contrary with Arginase-1 in the liver cancer of breaking up in various degree, Glypican-3 differentiated and benign tissue in liver tumour tissue are not expressed, and in the expression of PD hepatocellular carcinoma, have higher specificity.
SABC utilizes the principle of antigen and antibody specific binding, makes chromogenic reagent detect the existence of antigen in tissue specimen, and can position analysis by chemical reaction.Current SABC is widely used in Clinicopathologic Diagnosis, is a kind of detection means directly perceived, reliable.Immunohistochemistry pair is utilized to contaminate two the antigen presentation situations and mutual relation detected in same tissue in the present invention, can can observe two kinds of different antigen A rginase-1 and Glypican-3 expression same organizing in slice, thin piece, the differentiation for the good, pernicious of LCT and differentiation height has remarkable help.
Two transfection reagent boxes of a kind of, malignant tumour auxiliary diagnosis good for liver cell of the present invention, comprise following component: mixing primary antibodie is the mixed antibody of Arginase-1 and Glypian-3, mixing two resists for the anti-mixed antibody anti-with horseradish peroxidase-labeled sheep anti mouse two of alkali phosphatase enzyme mark goat-anti rabbit two, chromogenic reagent is AP-Red and DAB, TBS damping fluid.
Wherein, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 90-110 and 90-110.Wherein, the titre of the titre of Arginase-1 in mixing primary antibodie is 90, namely represents that Arginase-1 presses the dilution of 1:90.
Wherein, alkali phosphatase enzyme mark goat-anti rabbit two resists for alkali phosphatase enzyme mark goat anti-rabbit igg, and horseradish peroxidase-labeled sheep anti mouse two resists for horseradish peroxidase-labeled sheep anti-mouse igg.
Described mixing two anti-alkaline phosphatase mark goat-anti rabbit two is anti-to be mixed with the anti-1:1 by volume of horseradish peroxidase-labeled sheep anti mouse two.
The present invention also provides that a kind of described above pair of transfection reagent box is good auxiliary antidiastole liver cell, application in malignant tumour.
The present invention also provides a kind of nondiagnostic to differentiate, and liver cell is good, the detection method of malignant tumour, and wherein, use two transfection reagent box described above, its detection method comprises the following steps:
(0) histotomy 10% neutral formalin fixed, histotomy thickness is 2-5 μm.
(1) dewaxing and aquation: before dewaxing, the histotomy in step (0) is placed on 60 DEG C of roasting sheet machines and toasts 2 hours, then be placed in dimethylbenzene successively to soak 10 minutes twice, soak 5 minutes twice in absolute ethyl alcohol, soak 5 minutes in 95% ethanol once, soak 1 minute in distilled water once.Wherein, histotomy is placed on roasting sheet machine and toasts, section can be made to adhere to more firmly not easily flake, be also conducive to dewaxing.
(2) antigen retrieval: (pH value of EDTA antigen retrieval buffers, at 8.8-9.2, boils reparation particularly in pH9.0, cooling, tap water, distilled water immersion histotomy in step (1) to be placed on EDTA antigen retrieval buffers;
(3) close: in step (2), drip 3% hydrogen peroxide, incubated at room 10 minutes in histotomy, with distilled water flushing, TBS buffer solution for cleaning is also soaked;
(4) two dye: histotomy drips first antibody in step (3), namely Arginase-1 and Glypican-3 mixes primary antibodie, through incubated at room after 60 minutes, use TBS buffer solution for cleaning, drip second antibody, namely alkali phosphatase enzyme mark goat-anti rabbit two anti-anti-with horseradish peroxidase-labeled sheep anti mouse two mix two anti-, through incubated at room 60 minutes, use TBS buffer solution for cleaning, add developer DAB and AP-Red and develop the color;
(5) redye: histotomy in step (4) is put into haematoxylin solution and redyes, TBS damping fluid returns indigo plant;
(6) dewater: histotomy in step (5) is placed in 95% alcohol immersion 5 minutes, soaked in absolute ethyl alcohol 5 minutes twice;
(7) transparent: histotomy in step (6) to be placed in dimethylbenzene and to soak 5 minutes three times;
(8) mounting and be availablely placed in basis of microscopic observation and take pictures.
embodiment 1
Research object is that-paraffin-embedded liver tubercle hyperplastic tissue (being provided by Guangzhou Da'An Clinical Laboratory Center Co., Ltd) fixed by formalin.Immunohistochemical assay step is as follows:
(1) dewaxing and aquation: before dewaxing histotomy is placed on 60 DEG C of roasting sheet machine upper 2 hours.Be placed in dimethylbenzene to soak 10 minutes twice, soak 5 minutes twice in absolute ethyl alcohol, soak 5 minutes in 95% ethanol once, soak 1 minute in distilled water once.
(2) antigen retrieval: histotomy in step (1) is boiled reparation in EDTA (pH9.0) antigen retrieval buffers, cooling, tap water, distilled water immersion.
(3) close: histotomy 3% hydrogen peroxide at room temperature in step (2) is hatched 10 minutes, distilled water flushing, and TBS buffer solution for cleaning is also soaked.
(4) two dye: histotomy drips first antibody in step (3), namely Arginase-1 and Glypican-3 mixes primary antibodie, wherein, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 100 and 100, through incubated at room after 60 minutes, use TBS buffer solution for cleaning, drip second antibody, namely alkali phosphatase enzyme mark goat-anti rabbit two anti-anti-with horseradish peroxidase-labeled sheep anti mouse two mix two anti-, through incubated at room 60 minutes, use TBS buffer solution for cleaning, add developer DAB and AP-Red and develop the color.
(5) redye: haematoxylin is redyed, TBS damping fluid returns indigo plant.Haematoxylin returns blue object after redying be make nucleus present blueness, and returning the blue time will determine according to tissue, and Fan Lan limit, limit is observed.
(6) dewater: soak 5 minutes in 95% ethanol, soak 5 minutes twice in absolute ethyl alcohol.
(7) transparent: to soak 5 minutes three times in dimethylbenzene.
(8) mounting.
Histotomy in embodiment is placed in basis of microscopic observation and takes pictures.Fig. 1 is the expression of Arginase-1 and Glypican-3 in liver tubercle hyperplastic tissue.Result shows: in liver tubercle hyperplastic tissue, Arginase-1 positive expression (redness), and Glypican-3 is negative expression (brown).
Fig. 1 result illustrates: being expressed by the expression of Arginase-1 strong positive and Glypican-3 feminine gender can auxiliary diagnosis liver tumour benign lesion.
embodiment 2
Research object is that-paraffin-embedded low differentiated hepatocellular cancer (being provided by Guangzhou Da'An Clinical Laboratory Center Co., Ltd) fixed by formalin.Immunohistochemical assay step is as follows:
(1) dewaxing and aquation: before dewaxing histotomy is placed on 60 DEG C of roasting sheet machine upper 2 hours.Be placed in dimethylbenzene to soak 10 minutes twice, soak 5 minutes twice in absolute ethyl alcohol, soak 5 minutes in 95% ethanol once, soak 1 minute in distilled water once.
(2) antigen retrieval: the histotomy of step (1) is boiled reparation in EDTA (pH9.0) antigen retrieval buffers, cooling, tap water, distilled water immersion.
(3) close: the histotomy of step (2) is hatched 10 minutes with 3% hydrogen peroxide at room temperature, distilled water flushing, and TBS buffer solution for cleaning is also soaked.
(4) two dye: histotomy drips first antibody in step (3), namely Arginase-1 and Glypican-3 mixes primary antibodie, wherein, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 100 and 100, through incubated at room after 60 minutes, use TBS buffer solution for cleaning, drip second antibody, namely alkali phosphatase enzyme mark goat-anti rabbit two anti-anti-with horseradish peroxidase-labeled sheep anti mouse two mix two anti-, through incubated at room 60 minutes, use TBS buffer solution for cleaning, add developer DAB and AP-Red and develop the color.
(5) redye: haematoxylin is redyed, TBS damping fluid returns indigo plant.
(6) dewater: soak 5 minutes in 95% ethanol, soak 5 minutes twice in absolute ethyl alcohol.
(7) transparent: to soak 5 minutes three times in dimethylbenzene.
(8) mounting.
Histotomy in embodiment is placed in basis of microscopic observation and takes pictures.Fig. 2 is the expression of Arginase-1 and Glypican-3 in low differentiation liver cancer tissue.Fig. 2 result shows: in low differentiation liver cancer tissue, and Arginase-1 is negative expression (redness), Glypican-3 positive expression (brown).
Fig. 2 result illustrates: can auxiliary diagnosis malignant tumor of liver by the expression of Arginase-1 feminine gender and Glypican-3 positive expression.
embodiment 3
Research object is that-paraffin-embedded differentiated hepatocellular carcinoma (being provided by Guangzhou Da'An Clinical Laboratory Center Co., Ltd) fixed by formalin.Immunohistochemical assay step is as follows:
(1) dewaxing and aquation: before dewaxing histotomy is placed on 60 DEG C of roasting sheet machine upper 2 hours.Be placed in dimethylbenzene to soak 10 minutes twice, soak 5 minutes twice in absolute ethyl alcohol, soak 5 minutes in 95% ethanol once, soak 1 minute in distilled water once.
(2) antigen retrieval: the histotomy in step (1) is boiled reparation in EDTA (pH9.0) antigen retrieval buffers, cooling, tap water, distilled water immersion.
(3) close: the histotomy in step (2) is hatched 10 minutes with 3% hydrogen peroxide at room temperature, distilled water flushing, and TBS cleans and soaks.
(4) two dye: histotomy drips first antibody in step (3), namely Arginase-1 and Glypican-3 mixes primary antibodie, wherein, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 100 and 100, through incubated at room after 60 minutes, use TBS buffer solution for cleaning, drip second antibody, namely alkali phosphatase enzyme mark goat-anti rabbit two anti-anti-with horseradish peroxidase-labeled sheep anti mouse two mix two anti-, through incubated at room 60 minutes, use TBS buffer solution for cleaning, add developer DAB and AP-Red and develop the color.
(5) redye: haematoxylin is redyed, TBS damping fluid returns indigo plant.
(6) dewater: soak 5 minutes in 95% ethanol, soak 5 minutes twice in absolute ethyl alcohol.
(7) transparent: to soak 5 minutes three times in dimethylbenzene.
(8) mounting.
Histotomy in embodiment is placed in basis of microscopic observation and takes pictures.Fig. 3 is the expression of Arginase-1 and Glypican-3 in differentiated liver cancer tissue.Fig. 3 result shows: in differentiated liver cancer tissue, Arginase-1 positive expression (redness), Glypican-3 positive expression (brown), and two kinds of colors are all more weak.
Fig. 3 result illustrates: by the weak positive expression of Arginase-1 and the weak positive expression of Glypican-3 can auxiliary diagnosis liver tumour grade malignancy low.
To one skilled in the art, according to technical scheme described above and design, other various corresponding change and deformation can be made, and all these change and deformation all should belong within the protection domain of the claims in the present invention.
Claims (7)
1. two transfection reagent boxes for, malignant tumour auxiliary diagnosis good for liver cell, it is characterized in that, comprise mixing primary antibodie, described mixing primary antibodie is the mixed antibody of Arginase-1 and Glypian-3.
2. according to claim 1 pair of transfection reagent box, is characterized in that, in described mixing primary antibodie, the titre of Arginase-1 and Glypian-3 in mixing primary antibodie is respectively 90-110 and 90-110.
3. according to claim 1 pair of transfection reagent box, is characterized in that, this pair of transfection reagent box also comprises mixing two and resist, and described mixing two resists for the anti-mixed antibody anti-with horseradish peroxidase-labeled sheep anti mouse two of alkali phosphatase enzyme mark goat-anti rabbit two.
4. according to claim 1 pair of transfection reagent box, is characterized in that, this pair of transfection reagent box also comprises chromogenic reagent AP-Red and DAB, and TBS damping fluid.
5. the application in a transfection reagent box as claimed in claim 1 two, malignant tumour good auxiliary antidiastole liver cell.
6. nondiagnostic differentiates that liver cell is good, a detection method for malignant tumour, it is characterized in that, use two transfection reagent box as claimed in claim 1, its detection method comprises the following steps:
(1) dewaxing and aquation: before dewaxing, histotomy is placed on roasting sheet machine and toasts, be then placed in dimethylbenzene, absolute ethyl alcohol, 95% ethanol and distilled water successively and soak;
(2) antigen retrieval: histotomy in step (1) is placed in EDTA antigen retrieval buffers and boils reparation, cooling, tap water, distilled water immersion;
(3) close: in step (2), add 3% hydrogen peroxide, incubated at room in histotomy, with distilled water flushing, TBS buffer solution for cleaning is also soaked;
(4) two dye: histotomy drips mixing primary antibodie in step (3), after incubated at room, TBS buffer solution for cleaning, drip mixing two and resist, through incubated at room, TBS buffer solution for cleaning, adds developer DAB and AP-Red and develops the color;
(5) redye: histotomy in step (4) is put into haematoxylin solution and redyes, TBS damping fluid returns indigo plant;
(6) dewater: histotomy in step (5) is placed in 95% ethanol, absolute ethyl alcohol soaks successively;
(7) transparent: histotomy in step (6) to be placed in dimethylbenzene and to soak;
(8) mounting.
7. detection method according to claim 6, is characterized in that, also comprise the pre-treatment step to histotomy in step (1), this histotomy 10% neutral formalin is fixed, and histotomy thickness is 2-5 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510085335.2A CN104730242A (en) | 2015-02-15 | 2015-02-15 | Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510085335.2A CN104730242A (en) | 2015-02-15 | 2015-02-15 | Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104730242A true CN104730242A (en) | 2015-06-24 |
Family
ID=53454339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510085335.2A Pending CN104730242A (en) | 2015-02-15 | 2015-02-15 | Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104730242A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104792988A (en) * | 2015-02-15 | 2015-07-22 | 广州安必平医药科技股份有限公司 | Double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof |
| CN104990781A (en) * | 2015-06-29 | 2015-10-21 | 中国医学科学院皮肤病研究所 | Immunohistochemical hematoxylin-toluidine blue double-redyeing method for melanocyte |
| CN105067813A (en) * | 2015-07-23 | 2015-11-18 | 丁晓昆 | Method for rapidly detecting T-synthase activity |
| CN107179406A (en) * | 2017-05-27 | 2017-09-19 | 福州迈新生物技术开发有限公司 | Immunohistochemical staining kit is marked cancer embolus more |
| CN107677827A (en) * | 2017-10-09 | 2018-02-09 | 亚能生物技术（深圳）有限公司 | A kind of double transfection reagent boxes of cervical carcinoma supplementary classification diagnosis and its application |
| CN109540829A (en) * | 2018-12-12 | 2019-03-29 | 暨南大学 | A kind of infrared spectroscopy detection technique is used for the method for making sample of Crohn disease antidiastole |
| CN111766385A (en) * | 2020-07-06 | 2020-10-13 | 河南赛诺特生物技术有限公司 | Immunohistochemical kit for rapidly identifying lung cancer and sclerosing lung cell tumor in operation |
| CN112305213A (en) * | 2019-07-26 | 2021-02-02 | 项征 | Rich-fractionation double-dyeing kit and use method thereof |
| CN112964877A (en) * | 2021-03-09 | 2021-06-15 | 河南赛诺特生物技术有限公司 | Immunohistochemical multiple staining kit and staining procedure for identifying mantle cell lymphoma |
| CN113008649A (en) * | 2021-03-26 | 2021-06-22 | 河南赛诺特生物技术有限公司 | Immunohistochemistry combined elastic fiber multiple dyeing kit, dyeing method and application |
| CN113295871A (en) * | 2021-07-02 | 2021-08-24 | 河南赛诺特生物技术有限公司 | Cocktail immunohistochemical kit for diagnosing breast cancer |
| CN117233393A (en) * | 2023-11-15 | 2023-12-15 | 四川大学华西医院 | Double-immunohistochemical staining kit and application thereof in identifying benign and malignant bile duct epithelial tumors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101586167A (en) * | 2009-07-17 | 2009-11-25 | 四川大学 | Diagnosis reagent for primary hepatocellular carcinoma, reagent kit and prevention and cure medicaments |
| CN103149358A (en) * | 2013-03-14 | 2013-06-12 | 福州迈新生物技术开发有限公司 | Histological classification immunohistochemical multiple staining detection method for lung cancer |
| CN103370335A (en) * | 2010-06-24 | 2013-10-23 | 莫德普罗有限公司 | Novel biomarkers of liver cancer |
| CN103389376A (en) * | 2013-08-21 | 2013-11-13 | 中南大学湘雅医院 | Kit for evaluating clinical staging and prognosis of hepatocellular carcinoma and application of ECSCR (endothelial cell-specific chemotaxis regulator) |
-
2015
- 2015-02-15 CN CN201510085335.2A patent/CN104730242A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101586167A (en) * | 2009-07-17 | 2009-11-25 | 四川大学 | Diagnosis reagent for primary hepatocellular carcinoma, reagent kit and prevention and cure medicaments |
| CN103370335A (en) * | 2010-06-24 | 2013-10-23 | 莫德普罗有限公司 | Novel biomarkers of liver cancer |
| CN103149358A (en) * | 2013-03-14 | 2013-06-12 | 福州迈新生物技术开发有限公司 | Histological classification immunohistochemical multiple staining detection method for lung cancer |
| CN103389376A (en) * | 2013-08-21 | 2013-11-13 | 中南大学湘雅医院 | Kit for evaluating clinical staging and prognosis of hepatocellular carcinoma and application of ECSCR (endothelial cell-specific chemotaxis regulator) |
Non-Patent Citations (3)
| Title |
|---|
| TAISEER R. IBRAHIM ET AL: "Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver", 《PATHOLOGY & ONCOLOGY RESEARCH》 * |
| 李杰 等: "免疫标志物在肝脏上皮性肿瘤诊断与鉴别诊断中的意义", 《中华病理学杂志》 * |
| 顾春燕 等: "精氨酸酶-1和磷脂酰肌醇蛋白聚糖-3联合检测在肝细胞癌鉴别诊断中的应用", 《中华消化杂志》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104792988A (en) * | 2015-02-15 | 2015-07-22 | 广州安必平医药科技股份有限公司 | Double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof |
| CN104990781A (en) * | 2015-06-29 | 2015-10-21 | 中国医学科学院皮肤病研究所 | Immunohistochemical hematoxylin-toluidine blue double-redyeing method for melanocyte |
| CN104990781B (en) * | 2015-06-29 | 2018-02-16 | 中国医学科学院皮肤病研究所 | The melanocyte SABC haematoxylin-dual staining counter of toluidine blue |
| CN105067813A (en) * | 2015-07-23 | 2015-11-18 | 丁晓昆 | Method for rapidly detecting T-synthase activity |
| CN107179406A (en) * | 2017-05-27 | 2017-09-19 | 福州迈新生物技术开发有限公司 | Immunohistochemical staining kit is marked cancer embolus more |
| CN107677827A (en) * | 2017-10-09 | 2018-02-09 | 亚能生物技术（深圳）有限公司 | A kind of double transfection reagent boxes of cervical carcinoma supplementary classification diagnosis and its application |
| CN109540829A (en) * | 2018-12-12 | 2019-03-29 | 暨南大学 | A kind of infrared spectroscopy detection technique is used for the method for making sample of Crohn disease antidiastole |
| CN112305213A (en) * | 2019-07-26 | 2021-02-02 | 项征 | Rich-fractionation double-dyeing kit and use method thereof |
| CN112305213B (en) * | 2019-07-26 | 2024-06-07 | 项征 | ; -Rich double-dyeing kit and application method thereof |
| CN111766385A (en) * | 2020-07-06 | 2020-10-13 | 河南赛诺特生物技术有限公司 | Immunohistochemical kit for rapidly identifying lung cancer and sclerosing lung cell tumor in operation |
| CN111766385B (en) * | 2020-07-06 | 2023-09-26 | 河南赛诺特生物技术有限公司 | Immunohistochemical kit for rapidly identifying lung cancer and sclerosing pulmonary cytoma in operation |
| CN112964877A (en) * | 2021-03-09 | 2021-06-15 | 河南赛诺特生物技术有限公司 | Immunohistochemical multiple staining kit and staining procedure for identifying mantle cell lymphoma |
| CN113008649A (en) * | 2021-03-26 | 2021-06-22 | 河南赛诺特生物技术有限公司 | Immunohistochemistry combined elastic fiber multiple dyeing kit, dyeing method and application |
| CN113295871A (en) * | 2021-07-02 | 2021-08-24 | 河南赛诺特生物技术有限公司 | Cocktail immunohistochemical kit for diagnosing breast cancer |
| CN117233393A (en) * | 2023-11-15 | 2023-12-15 | 四川大学华西医院 | Double-immunohistochemical staining kit and application thereof in identifying benign and malignant bile duct epithelial tumors |
| CN117233393B (en) * | 2023-11-15 | 2024-02-09 | 四川大学华西医院 | Double-immunohistochemical staining kit and application thereof in identifying benign and malignant bile duct epithelial tumors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104730242A (en) | Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof | |
| Molinié et al. | Diagnostic utility of a p63/α-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate | |
| Wiener et al. | Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? | |
| Paner et al. | Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies | |
| Sangoi et al. | Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases | |
| Brimo et al. | Immunohistochemical pitfalls in prostate pathology | |
| CN103149358B (en) | Histological classification immunohistochemical multiple staining detection method for lung cancer | |
| Shan et al. | Gradually increased G olgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients | |
| CN104297481A (en) | Double-label immunohistochemical staining kit used for differential diagnosis of metastatic renal cell carcinoma | |
| CN103743904B (en) | A kind of two mark immunohistochemical staining kits for micro-wellability adenocarcinoma of lung | |
| Ren et al. | D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion | |
| Saito et al. | Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein | |
| Bertazzolo et al. | Cytologic features and diagnostic accuracy of analysis of effusions for detection of ovarian carcinoma in dogs | |
| Huang et al. | NKX3. 1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens | |
| CN103196731A (en) | Multiple stain reagent and detection method for identifying breast myoepithelial lesion | |
| CN103471903B (en) | The collocation method of section immobile liquid and application thereof | |
| CN103592444A (en) | Method for detecting cyclin G1 protein expression in breast cancer and carrying out prognosis evaluation | |
| CN102260731B (en) | Enzyme-labeling-liquid-based cytology staining kit for screening bladder cancer | |
| Ying et al. | Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma | |
| Jin et al. | Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma | |
| CN112305213A (en) | Rich-fractionation double-dyeing kit and use method thereof | |
| Xu et al. | Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma | |
| Zheng et al. | Uncovering the heterogeneity and clinical relevance of circulating tumor-initiating cells in hepatocellular carcinoma using an integrated immunomagnetic-microfluidic platform | |
| Hou et al. | Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens | |
| CN104792988A (en) | Double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150624 |